NASDAQ:REVB Revelation Biosciences Q4 2025 Earnings Report $0.76 -0.04 (-4.67%) Closing price 10/2/2026 03:59 PM EasternExtended Trading$0.81 +0.05 (+6.34%) As of 10/2/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Revelation Biosciences EPS ResultsActual EPS-$1.65Consensus EPS -$1.41Beat/MissMissed by -$0.24One Year Ago EPSN/ARevelation Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ARevelation Biosciences Announcement DetailsQuarterQ4 2025Date2/26/2026TimeBefore Market OpensConference Call DateThursday, February 26, 2026Conference Call Time7:00AM ETUpcoming EarningsRevelation Biosciences' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Revelation Biosciences Earnings HeadlinesRevelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN StudyAugust 19, 2026 | finance.yahoo.comREVB approaching a critical inflection pointAugust 7, 2026 | msn.comA new type of AI could unleash gains of up to 10,000%A new AI category called Accelerated AI is starting to gain traction, and most investors haven't caught on yet. Early movers in past technology shifts have seen outsized results, and this emerging niche is drawing comparisons. Get the name and ticker of the leading Accelerated AI company making waves right now.October 4 at 1:00 AM | Brownstone Research (Ad)Revelation Biosciences, Inc.: Revelation Biosciences Announces Adoption of Stockholder Rights PlanJuly 10, 2026 | finanznachrichten.deREVB Poised for Big YearMay 8, 2026 | finance.yahoo.comRevelation Biosciences (REVB) price target decreased by 37.65% to 54.06March 28, 2026 | msn.comSee More Revelation Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Revelation Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Revelation Biosciences and other key companies, straight to your email. Email Address About Revelation BiosciencesRevelation Biosciences (NASDAQ:REVB) is a clinical-stage biotechnology company focused on developing immunologic therapies for diseases with significant unmet medical needs. The company’s research is centered on therapeutics designed to stimulate or modulate the body’s innate immune system, the first line of defense against infection and other disease processes. Its development pipeline has included REVTx-99, an investigational intranasal therapy based on a proprietary beta-glucan formulation. The candidate has been studied for its potential to help prevent or reduce the severity of respiratory viral infections and associated complications, including acute respiratory distress. Revelation Biosciences has also evaluated additional immune-modulating product candidates and formulations as part of its broader platform. The company is headquartered in San Diego, California, and has focused its clinical development activities on potential applications in respiratory and infectious diseases. As an emerging biotechnology company, Revelation Biosciences’ programs remain subject to clinical, regulatory, and commercial development risks, and its investigational products have not necessarily been approved for marketing.View Revelation Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/28 - 10/02Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?Time to Nibble on MCD Stock After it Enters Oversold Territory?Liberty Energy’s AI Power Push Has Wall Street DividedMcCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the Test Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
